Browsing by Subject "PARP inhibitors"
Now showing items 1-2 of 2
-
A review on newly approved PARP inhibitors: Talazoparib and Olaparib
(Brac University, 2024-01)This review delves into the intricate landscape of Poly ADP-ribose polymerase (PARP) inhibitors, specifically focusing on two notable contenders in cancer therapy – Talazoparib and Olaparib. By targeting the DNA Damage ... -
A review on potential of PARP inhibitors in the treatment of prostate cancer
(Brac University, 2022-05)Prostate cancer is still a fatal disease at metastatic castration resistance stage (mCRPC) in spite of pursuing advancements in patient survival, indicating the necessity of therapeutic approaches. A significant number of ...
